Scientific Research Publishing

International Journal of Clinical Medicine, 2025, 16(2), 135-153
https://www.scirp.org/journal/ijcm
ISSN Online: 2158-2882
ISSN Print: 2158-284X

Encrypting Cancer's Morse Code: The Synergistic Power of CD47-SIRPα Blockade and Tyrosine Kinase Inhibition

Mahamud Hirsi, Yahya Lahrach, Abdirahman Mohamud Abdirahman, Amina Nazir, Mohamed Abshir Barre, Yasmine Yusuf Hussein Dinle, Abdulrahman Wajih Alkhatib, Biradar Rohan Nagendrappa

College of Basic Medince and Science, Jilin University, Changchun, China
Email: mahamud18hirsi@gmail.com

How to cite this paper: Hirsi, M., Lahrach, Y., Abdirahman, A.M., Nazir, A., Barre, M.A., Dinle, Y.Y.H., Alkhatib, A.W. and Nagendrappa, B.R. (2025) Encrypting Cancer's Morse Code: The Synergistic Power of CD47-SIRPα Blockade and Tyrosine Kinase Inhibition. *International Journal of Clinical Medicine*, **16**, 135-153.
https://doi.org/10.4236/ijcm.2025.162009

Received: January 18, 2025
Accepted: February 25, 2025
Published: February 28, 2025

Abstract

Modern medicine faces the formidable challenge of cancer because of its ability to evade immune surveillance and cultivate resistance to conventional therapies. Cancer cells, when overexpressed with CD47, send a "don't eat me" signal to macrophages, successfully shielding them from immune destruction. Similarly, tyrosine kinase inhibitors (TKIs) have revolutionized cancer treatment by targeting oncogenic pathways, but their effectiveness is often compromised by resistance and minimal residual disease. This review explores a novel combination of CD47-SIRP-blockade and TKIs, addressing the limitations of monotherapies in cancer treatment. Disrupting the CD47-SIRPα interaction stimulates macrophage-mediated phagocytosis and revives exhausted T cells, while TKIs simultaneously target tumor growth drivers. Confirmation from preclinical studies indicates that this combination is capable of enhancing antitumor immunity and remodeling tumor microenvironments for enhanced therapeutic outcomes. However, hematotoxicity and tumor heterogeneity present challenges in the path to clinical translation. This review presents current findings, identifies key research areas, and proposes future directions to enhance this combinatorial approach. In the midst of a new era in cancer treatment, immune modulation combined with targeted therapies promises to offer more effective, less toxic, and personalized treatment options. This combination approach has the potential to significantly improve cancer treatment strategies by overcoming current therapeutic limitations.

Keywords

CD47, Tyrosine Kinase Inhibitors, Cancer Immune Evasion, Tumor Microenvironment, Targeted Cancer Therapy, Immune Checkpoint Inhibitors

1. Introduction

Cancer is driven by uncontrolled cell growth driven by a combination of genetic mutations and environmental factors. The progression and metastasis of cancer involve a variety of mechanisms, including genetic alterations, epigenetic changes, and intricate interactions within the tumor microenvironment [1]. Amid the many challenges in oncology, cancer cachexia—a syndrome characterized by severe weight loss and muscle wasting—complicates treatment and significantly reduces survival rates, affecting nearly half of all cancer patients [2]. This underscores the evolving nature of cancer and the difficulty in making long-term predictions about mortality due to its diverse manifestations [3]. Cancer remains a global health challenge, amplified by socioeconomic disparities, drug resistance, and governance issues. Poverty remains a critical factor in cancer disparities, particularly in low- and middle-income countries (LMICs), where approximately 70% of cancer deaths occur. These regions urgently require tailored cancer governance and resource allocation mechanisms to improve outcomes [4].

A significant obstacle in cancer treatment is the phenomenon of drug resistance, particularly due to the emergence of drug-tolerant "persister" cells that survive therapies and contribute to relapse [5]. The tumor microenvironment (TME) further complicates this by fostering the selection of resistant clones, thereby challenging the efficacy of conventional treatments [6]. Therefore, addressing these issues requires a comprehensive, versatile approach that integrates socioeconomic, biological, and governance strategies to enhance cancer treatment and patient survival.

Central to the immune evasion tactics employed by cancer cells is the CD47-SIRPα pathway. CD47, a transmembrane protein, is overexpressed in various cancers, enabling tumors to avoid detection and destruction by the immune system [7] [8]. By binding to SIRPα on macrophages, CD47 sends a "don't eat me" signal, which inhibits phagocytosis and allows cancer cells to thrive unchecked [7]. High levels of CD47 are correlated with poor prognoses across multiple cancer types, including colorectal and ovarian cancers, where it supports tumor growth through enhanced angiogenesis and resistance to apoptosis [9] [10]. The therapeutic potential of targeting the CD47-SIRPα pathway is promising, with monoclonal antibodies showing potential in clinical trials by enhancing macrophage-mediated phagocytosis and improving patient outcomes [10] [11]. In spite of this, challenges remain, particularly concerning safety and specificity, as systemic immune modulation could lead to unintended consequences such as increased inflammation or autoimmunity. Therefore, it is essential that further research is conducted to refine these therapeutic strategies.

A novel and potentially transformative approach in cancer therapy involves the combination of CD47-SIRPα blockade with tyrosine kinase inhibitors (TKIs). This approach has shown particular promise in hematologic malignancies (e.g. acute myeloid leukemia and diffuse B-cell lymphoma) and solid tumors such as

non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) where high CD47 expression is correlated with poor prognosis. Combining CD47 Blockade with TKIs may increase anti-tumor effects by encouraging immune cell infiltration and activation, as evidenced in studies illustrating improved macrophage responses with dual blockade strategies [12]. This synergistic strategy has shown promise in preclinical models, particularly in improving outcomes for patients with previously challenging solid tumors [13]. CD47-SIRPα blockade counteracts tumor immune evasion by stimulating macrophage-mediated phagocytosis, an additional mechanism that complements TKI therapy, which targets oncogenic signaling pathways. The CD47 blockade is different from other immune checkpoint inhibitors (e.g. PD-1/PD-L1) because it influences the innate as well as the adaptive immune systems. Making it an effective option for combination therapies in resistant cancers. However, it is important to note that drug resistance as well as toxicity remain significant challenges [14] [15].

The combination of CD47-SIRPα blockade with TKIs represents a promising frontier in oncology, offering a dual approach that addresses the limitations of monotherapies and enhances anti-tumor immunity. As research in this field progresses, this combination strategy may pave the way for more effective, less toxic, and highly personalized cancer therapies, bringing us closer to achieving durable and therapeutic treatment outcomes. Therefore, this study aims to explore the therapeutic potential of combining CD47-SIRPα blockade with tyrosine kinase inhibitors to enhance anti-tumor immunity, overcome drug resistance, and improve treatment outcomes in cancer.

2. The CD47-SIRPα Pathway in Cancer Immune Evasion

The CD47-SIRPα pathway is a cornerstone in cancer's ability to evade immune detection, acting as a powerful "don't eat me" signal that shields tumor cells from macrophages. By overexpressing CD47, cancer cells effectively instruct immune cells to ignore them, allowing the tumor to grow and spread undetected. This pathway has emerged as a primary target in cancer therapy, with the potential to disrupt this immune evasion and enhance the body's natural defenses against malignancy. Understanding and targeting the CD47-SIRPα axis could pave the way for breakthroughs in cancer treatment.

2.1. Mechanisms of Immune Evasion

The CD47 protein, often overexpressed in various cancers, including lung cancer, plays a critical role in immune evasion by sending a "don't eat me" signal to macrophages, thus inhibiting their phagocytic activity [7] [16]. This overexpression is not just a passive trait of tumor cells; in non-small cell lung cancer (NSCLC), mutations in the epidermal growth factor receptor (EGFR) are known to upregulate CD47, further impeding macrophage function and promote tumor growth [17]. This mechanism enables cancer cells to escape immune surveillance, contributing to disease progression and resistance to therapy.

2.2. Impact on Immune Cells

The CD47-SIRPα interaction does more than just prevent macrophage phagocytosis; it also plays a significant role in regulating the broader immune response. For example, CD47's inhibition of immune activity can lead to CD4+ T cell exhaustion, weakening the body's ability to fight the tumor [18]. This finding underscores the potential of targeting CD47 to rejuvenate T cell activity and improve outcomes in immunotherapy. By disrupting this pathway, there is potential to reinvigorate exhausted T cells and enhance anti-tumor immunity [19], which could significantly impact the effectiveness of ongoing cancer treatments.

2.3. Therapeutic Implications

Given its role in immune evasion, the CD47-SIRPα axis has become a promising target for cancer therapy. Inhibitors of this pathway, such as anti-CD47 antibodies, are currently under investigation in clinical trials, with preliminary results revealing enhanced macrophage phagocytosis and improved anti-tumor responses. On the other hand, challenges remain, including potential adverse effects and the need to ensure specificity and safety in therapy [16] [19]. Moreover, Research is also exploring SIRPα as a narrower target, primarily in cancers where CD47 blockade alone may not be sufficient.

3. Molecular Mechanisms of CD47-SIRPα Interaction

The interaction between CD47 and SIRPα is not just a surface-level connection; it is a well-orchestrated molecular phenomenon. Molecular dynamics simulations have revealed that specific residues, such as Glu35 and Tyr37 in CD47, play a critical role in this binding, forming a distinctive groove that facilitates the interaction with SIRPα [20]. This precise binding mechanism is key to the "don't eat me" signal that cancer cells exploit. Therefore, understanding these molecular details is essential for developing more effective inhibitors that can disrupt this interaction and restore immune function [21] [22]. In contrast, a collection of studies suggests that this axis might function beyond immune evasion, potentially altering macrophage polarization and tumor microenvironment dynamics, indicating an interplay that warrants further study.

3.1. SIRPα Signaling and Macrophage Response

Beyond the horizon of just blocking phagocytosis, the CD47-SIRPα interaction also influences macrophage polarization and the tumor microenvironment. To illustrate, in NSCLC, blocking SIRPα has been shown to reduce IL-6 levels and decrease the presence of immunosuppressive M2 macrophages, thereby enhancing anti-tumor immunity [23]. In a similar manner, in high-risk neuroblastoma, targeting SIRPα could shift macrophage polarization towards a more pro-inflammatory state, accelerating tumor clearance. Additionally, emerging research highlights the role of microRNAs, such as miR-378a, which modulates SIRPA, influencing macrophage phagocytosis and differentiation. Atherosclerosis models with reduced miR-378a expression show

decreased phagocytic activity [24], in regulating this pathway, further adding complexity to its role in cancer progression and offering new avenues for therapeutic intervention. In summary, SIRPA signaling plays a crucial role in shaping macrophage responses, which has implications for cancer therapy and inflammatory diseases. Despite its complexity, its regulation, including the involvement of microRNAs calls for a refined approach to therapeutic targeting.

3.2. CD47-SIRPα Pathway in Tumor Microenvironment

The CD47-SIRPα pathway plays a crucial role in the tumor microenvironment by inhibiting macrophage phagocytosis of cancer cells [25] [26]. This pathway mediates the "don't eat me" signal within the tumor microenvironment, contributing to the suppression of anti-tumor immunity. Tumors often overexpress CD47 to evade immune destruction, and this overexpression can also influence other immune cells within the microenvironment, such as myeloid-derived suppressor cells (MDSCs), which further enhance immunosuppressive functions [27]. Blocking the CD47-SIRPα interaction has been shown to improve macrophage-mediated phagocytosis and reduce tumor burden, particularly in models of diffuse large B cell lymphoma [28]. This blockade not only enhances the direct phagocytic activity of macrophages but also influences the broader immune response by reducing the immunosuppressive effects of MDSCs and potentially altering the tumor microenvironment to favor anti-tumor immunity. Conversely, further research is needed in order to optimize these therapeutic strategies to ensure safety and efficacy in a clinical setting.

3.3. Therapeutic Developments and Future Directions

Targeting the CD47-SIRPα axis presents a promising avenue in cancer therapy, with ongoing clinical trials evaluating approaches such as SIRPα fusion proteins to improve efficacy and reduce adverse effects. Despite that, while these therapies hold promise, further research is necessary to optimize their use and ensure they are both safe and effective in a clinical environment.

4. Therapeutic Targeting of CD47 in Cancer

The therapeutic targeting of CD47 has emerged as a promising strategy in cancer treatment, particularly due to its role in inhibiting phagocytosis and serving as an immune checkpoint. Recent advances focus on unfolding anti-CD47 therapies to improve immune responses and reduce the side effects.

4.1. Development of Anti-CD47 Monoclonal Antibodies

Monoclonal antibodies against CD47 have gained significant attention for their ability to promote macrophage-mediated phagocytosis of tumor cells. Agents such as IMC-002 and MIL95 have shown promise in early-phase trials, demonstrating manageable safety profiles and preliminary efficacy in advanced solid tumors without dose-limiting toxicities [29] [30]. Furthermore, Fc-engineered variants of

these antibodies have been engineered to increase binding to target FcγRs, thereby enhancing systemic anti-tumor immunity and reducing off-target effects [31]. Innovations such as pH-dependent anti-CD47 antibodies, highlighted by BC31M4, selectively target tumors in acidic microenvironments, reducing side effects on healthy tissue [32].

4.2. Fusion Proteins and Bispecific Antibodies Targeting CD47

The development of fusion proteins and bispecific antibodies has introduced novel approaches to CD47-targeted therapy. These therapies aim to enhance immune responses while minimizing adverse effects. For instance, a bispecific antibody targeting both CD38 and CD47 has demonstrated potent inhibition of tumor growth in hematologic malignancies, enhancing antibody-dependent cellular cytotoxicity (ADCC) with minimal off-tumor effects [33]. Similarly, dual targeting of CD47 and PD-L1 by agents like Papiliximab has shown effectiveness in tumor growth inhibition without causing hemolysis [34].

4.3. Clinical Trials and Therapeutic Outcomes

Despite the promising developments in CD47-targeted therapies, challenges persist, particularly regarding safety and efficacy. CD47 is widely expressed in healthy cells, which raises concerns about adverse effects such as anemia and other hematological disorders. Clinical trials have highlighted the need for combination strategies to enhance the anti-tumor activity of these therapies. As demonstrated, combining anti-CD47 therapies with other treatments, such as anti-VEGF, has shown enhanced anti-tumor effects in preclinical models [35]. However, further refinement is required to maximize therapeutic potential and minimize side effects.

5. Tyrosine Kinase Inhibitors (TKIs) in Cancer Treatment

Tyrosine kinase inhibitors (TKIs) have revolutionized cancer treatment by targeting specific oncogenic kinases involved in tumor growth and survival. Despite their achievements, resistance and side effects require continuous research.

5.1. Overview of TKIs: Mechanisms and Targets

TKIs function by inhibiting the tyrosine phosphorylation process is crucial for various cellular activities such as cell proliferation and survival [36] [37]. These drugs target specific mutations in kinases, like BCR-ABL and EGFR, which are commonly implicated in cancers such as chronic myeloid leukemia (CML) and non-small cell lung cancer (NSCLC). However, the efficacy of TKIs is often compromised by resistance mechanisms, including mutations in kinase domains and alternative signaling pathways [14].

5.2. Successes and Limitations of TKI Therapy

TKI therapy has significantly improved survival rates and quality of life in patients with certain cancers. For instance, elderly patients with CML have an overall survival

rate of 71.9% five years post-treatment with optimal doses of TKIs [38]. However, the therapy is not without limitations; adverse effects such as significant toxicities in medullary thyroid cancer (MTC) and the risk of therapy failure in approximately 20% - 30% of CML patients underscore the need for better management strategies [39].

5.3. Development of Resistance in TKI Monotherapy

Resistance to TKI monotherapy still represents a significant barrier to cancer treatment. Mechanisms such as the activation of TRAF6/MAPK/AP-1 pathways in clear cell renal cell carcinoma (ccRCC) and MET gene amplification in NSCLC contribute to acquired resistance [40] [41]. However, to overcome this, combination therapies with other agents, such as HDAC inhibitors or chemotherapy, have shown promise in reversing resistance and improving treatment outcomes [42].

6. Combining TKIs with CD47-SIRPα Blockade: A New Therapeutic Frontier

Synthesizing TKIs with CD47-SIRPα blockade is a fresh perspective to enhancing anti-tumor immunity, predominantly in solid tumors like RCCs). This approach employs the supporting mechanisms of TKIs and CD47 blockade to promote tumor clearance and improve patient outcomes.

6.1. Rationale for Combining TKIs with CD47 Blockade

CD47-SIRPα blockade enhances macrophage-mediated tumor cell clearance by inhibiting the "don't eat me" signal provided by CD47, particularly in RCCs where high CD47 expression is related to poor outcomes [43]. When combined with TKIs, this approach not only promotes macrophage activation but also enhances trogocytosis, further boosting anti-tumor effects [43].

6.2. Preclinical Evidence Supporting Combination Therapy

Preclinical studies have demonstrated the synergistic potential of combining CD47 blockade with TKIs. For example, in head and neck squamous cell carcinoma, CD47 blockade enhanced macrophage adhesion and improved antibody-dependent cellular phagocytosis (ADCP) when combined with cetuximab, a TKI [44]. Furthermore, studies combining radiotherapy with CD47 inhibition have shown macrophage-mediated abscopal effects, improving tumor control beyond the site of radiation [45].

6.3. Challenges and Future Directions for Combination Strategies

Despite the potential of combining TKIs with CD47 blockade, several challenges remain. The suppressive tumor microenvironment and the risk of anemia due to CD47's expression on erythrocytes complicate treatment [19]. Future research should focus on optimizing dosing and patient selection, and exploring the use of hybrid nanoplatforms to deliver CD47-targeting agents alongside chemotherapy to enhance

efficacy and minimize adverse effects [46].

The combination of CD47-SIRPα blockade with tyrosine kinase inhibitors provides notable promise for cancer treatment, offering a potential new therapeutic frontier. While challenges remain, particularly in terms of safety and resistance mechanisms, ongoing research and innovation are forecasted to develop new strategies that enhance the efficacy of these therapies and improve patient outcomes. This collaborative approach showcases the future of cancer treatment, where targeted therapy and immune modulation work in concert to defeat the complexities of the disease.

7. CD47-SIRPα Blockade: A Revolutionary Approach in Cancer Therapy

CD47, often referred to as the "don't eat me" signal, is a transmembrane protein overexpressed in various malignancies, playing a crucial role in immune evasion by inhibiting phagocytosis via its interaction with SIRPα on macrophages. Blockade of the CD47-SIRPα axis has been identified as an effective strategy to re-engage the immune system in the fight against cancer. However, the inconsistency in clinical outcomes has posed significant challenges.

7.1. Tumor Microenvironment and CD47 Expression

High CD47 expression correlates with a poor prognosis in diffuse large B-cell lymphoma (DLBCL), characterized by an immunosuppressive microenvironment and increased macrophage infiltration. This suggests that CD47-targeted therapies may be less effective in patients with elevated CD47 levels, requiring a deeper understanding of the tumor microenvironment and its influence on therapy efficacy [47].

7.2. Genetic Factors and Therapy Efficacy

The effectiveness of CD47-targeted therapies is further complicated by genetic factors, with CD47 overexpression often parallel to mutations in oncogenes such as TBL1XR1 and NOTCH1. These genetic alterations can lead to inconsistent therapeutic responses, underscoring the need for personalized approaches in CD47 blockade therapy [47].

7.3. Preclinical Insights and Clinical Challenges

Preclinical studies with CD47-targeted CAR T cells have shown limited efficacy due to fratricide and poor expansion [48], highlighting the challenges in translating these therapies from bench to bedside. Clinical trials have also encountered setbacks, with some CD47-targeting agents proving ineffective as monotherapies [49].

8. Challenges in CD47-Targeted Therapies: Overcoming the Hurdles

8.1. Regulatory Complexities

There are a number of factors that play a significant role in regulating the expression

of CD47, which is important for evading the immune system of cancer cells. MiR-101-5p, in particular, has been identified as a key regulator of CD47 expression. A high level of miR-101-5p enhances macrophage phagocytosis, which improves treatment response in cancers such as diffuse large B-cell lymphoma. There is evidence that miR-101-5p can predict the efficacy of CD47-targeted therapies, indicating a need to investigate microRNA-based strategies for cancer treatment [49]. Despite this, tumor heterogeneity complicates this approach. Different tumor types and tumors within the same type can express CD47 differently, affecting therapeutic response consistency. CD47 blockade may not always work uniformly on tumors with high CD47 expression due to factors such as tumor microenvironment and genetics, which led to disappointing outcomes in recent clinical trials, highlighting the need for more refined regulatory mechanisms [50].

8.2. Hematotoxicity

Hematotoxicity, particularly anemia, remains a significant barrier to the development of CD47 blockade therapies. This adverse effect has not only narrowed the therapeutic window but has also led to the discontinuation of several trials. Ongoing research aims to mitigate this toxicity, but effective strategies are still under exploration [51]. In future clinical trials exploring CD47 blockade, hematotoxicity will be a crucial factor in ensuring its feasibility and safety. Considering lower doses or extended dosing intervals will minimize anemia while still maintaining therapeutic efficacy in future clinical studies. In addition to erythropoiesis-stimulating agents (ESAs) and iron supplementation, other approaches to managing hematologic side effects include CD47-targeted treatments that can prevent anemia. Furthermore, early detection of hematotoxicity via biomarkers is critical for personalized treatment, allowing adjustments according to individual responses and preventing more severe adverse effects. The key to overcoming hematotoxicity and improving the safety profile of CD47 blockade therapies will be to optimize dosing, combine supportive therapies, and monitor hematologic status early.

8.3. Tumor Microenvironment

The immunosuppressive tumor microenvironment, marked by M2 macrophage polarization in the presence of CD47 overexpression, further complicates the effectiveness of CD47-targeted therapies [47]. This necessitates the development of combinatorial approaches to enhance therapeutic efficacy [16].

8.4. Bridging the Gap: From Preclinical Models to Clinical Triumph in CD47-SIRPα Blockade

Although current preclinical models of CD47-SIRPα blockade show promise, they still fall short of accurately replicating the complexity of the human tumor microenvironment (TME), which includes immune cell interactions and tumor heterogeneity, all of which greatly affect the effectiveness of therapy. Research should focus on improving preclinical models by incorporating patient-derived xenografts (PDXs)

and organ-on-a-chip technologies that more closely mimic human immune responses and tumor characteristics. Additionally, for clinical translation to be successful, it is crucial to identify biomarkers, such as CD47 expression levels, macrophage activation markers, and immune cell infiltration markers. This will facilitate more accurate patient stratification and enhance therapeutic efficacy. It may also be possible to monitor these biomarkers in real time using liquid biopsies, allowing for personalized treatment adjustments. Aside from hematotoxicity, the challenge of managing anemia remains. Efforts should be made to mitigate these effects by optimizing doses, using erythropoiesis-stimulating agents (ESAs), and supplementing iron in future trials. Finally, adaptive trial designs will be crucial to identifying optimal dosing regimens and combination therapies, allowing for adjustments based on patient response and ultimately improving clinical success.

Critical Analysis of Cited Studies and Limitations in Combination Therapy

A combination of CD47-SIRPα blockade and tyrosine kinase inhibitors (TKIs) holds significant promise in cancer therapy, especially for cancers where CD47 overexpression facilitates immune evasion, such as non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) [7] [16]. Using this approach, macrophage-mediated phagocytosis can be enhanced and immune cells can be stimulated, which provides an efficient complement to TKIs that target oncogenic signaling pathways. CD47 blockade with TKIs has been shown to improve tumor clearance and immune response in preclinical studies [43]. The results of studies on different cancer types are, however, contradictory. In contrast to RCC, other solid tumors, like head and neck squamous cell carcinoma, show mixed responses, with variable macrophage adhesion and antibody-dependent cellular phagocytosis (ADCP) [44]. Aside from hematotoxicity, particularly anemia, the combination of CD47 blockage with TKIs remains a critical concern due to CD47 expression on erythrocytes, complicating clinical implementation. Aside from hematotoxicity, particularly anemia, the combination of CD47 blockage with TKIs remains a critical concern due to CD47 expression on erythrocytes, complicating clinical implementation [19]. Moreover, immune resistance mechanisms, such as alternative immune checkpoints, can limit the therapeutic efficacy, emphasizing the need to identify biomarkers to improve patient selection and dose optimization. A novel combination strategy, such as pairing CD47 blockade with chemotherapy or radiotherapy, should be explored in the future to overcome these challenges and improve treatment outcomes [46]. In spite of the hurdles, combining CD47-SIRPα blockade and TKIs remains a promising avenue for enhancing anti-tumor immunity and overcoming cancer resistance.

9. Innovative Strategies to Enhance CD47-Targeted Therapy

To overcome the challenges associated with CD47-targeted therapies, a range of cutting-edge strategies have been introduced, focusing on combination therapies, advanced drug delivery systems, and Fc domain optimization.

9.1. Combination Therapies

Combining CD47 blockade with other therapeutic modalities has shown promise in enhancing anti-tumor responses. For instance, photodynamic therapy has been found to synergize with CD47 blockade by enhancing phagocytic activity and promoting dendritic cell maturation, thereby improving overall therapeutic outcomes [52].

In a comparable manner, the novel inhibitor HOSU-53 has demonstrated effective monotherapy in multiple myeloma while also synergizing with anti-CD47 therapies [53].

9.2. Advanced Drug Delivery Systems

The development of advanced drug delivery systems, such as engineering exosomes to display RGD and CD47p110-130, has remarkably improved the targeting of pancreatic cancer cells. These smart exosomes not only enhance targeting efficiency but also reduce clearance by mononuclear phagocytes, thereby increasing the therapeutic window [54].

9.3. Fc Domain Optimization

The optimization of Fc domains in anti-CD47 antibodies has been shown to encourage macrophage infiltration and subsequent T cell activation, which are vital for effective tumor control. This approach highlights the importance of Fc-FcR interactions in the anti-tumor activities of CD47-targeted therapies [31].

9.4. Tyrosine Kinase Inhibitors (TKIs) and CD47 Blockade: A Synergistic Duo

Tyrosine kinase inhibitors (TKIs) have become a fundamental element in targeted cancer therapy, particularly in malignancies driven by specific oncogenic kinases. The combination of TKIs with CD47 blockade represents a promising strategy to overcome resistance and improve treatment effectiveness.

9.5. Clinical Applications

The synergistic effect of TKIs and CD47 blockade has been demonstrated in various preclinical models, paving the way for clinical trials exploring this combination in different cancer types. Early results suggest that this dual approach could lead to more durable responses and improved patient outcomes compared to monotherapies [53].

9.6. Future Directions

The integration of CD47-SIRPα blockade with TKIs holds significant potential, but critical challenges must be addressed to advance this strategy. First, systemic CD47 blockade often causes anemia and thrombocytopenia due to on-target/off-tumor effects; tumor-specific CD47 delivery systems (e.g. bispecific antibodies, nanocarriers) or optimized dose-escalation protocols should be prioritized to mitigate

toxicity. Second, current preclinical models, such as immunocompromised mice, poorly replicate human immune-tumor interactions; humanized mouse models or 3D patient-derived organoids with intact immune components are urgently needed to improve clinical translatability. Third, the mechanisms underlying resistance to TKI-CD47 combinations remain unclear; single-cell RNA sequencing of the tumor microenvironment post-therapy could identify drivers of immune evasion and guide rational drug sequencing.

To refine patient selection, biomarker validation is essential: candidate markers like CD47/SIRPα expression levels, PD-L1 status, and tumor mutational burden should be prospectively tested in clinical cohorts. Additionally, adaptive trial designs incorporating biomarker-guided arms (e.g. CD47-high vs. CD47-low subgroups) will help define responsive populations. Systematic testing of TKI-CD47 dosing schedules (concurrent vs. staggered) is essential to optimize the balance between efficacy and safety. Longitudinal immune monitoring should also be incorporated to evaluate adaptive memory responses and potential autoimmune risks. Additionally, combining TKI-CD47 therapies with radiotherapy or chemotherapy could enhance antigen release and immune priming, while SIRPα occupancy assays may provide valuable pharmacodynamic markers to inform dosing strategies. By addressing these challenges and implementing actionable strategies—ranging from improved preclinical models to biomarker-driven clinical trials—this combination approach has the potential to address current limitations and contribute meaningfully to the advancement of precision oncology.

10. Future Perspectives

10.1. Next Generation of CD47-Targeted Therapies

The field of CD47-targeted therapies is on the brink of a paradigm shift, with emerging therapies poised to not only enhance efficacy but also minimize adverse effects. These advancements are expected to redefine cancer treatment strategies by leveraging novel antibodies and intricate regulatory mechanisms.

10.2. Novel Antibodies

The development of "Gentulizumab", a humanized anti-CD47 monoclonal antibody, marks a significant breakthrough in oncology. This antibody exhibits potent anti-tumor activity while maintaining a favorable safety profile, primarily by inhibiting CD47-SIRPα interactions, thereby amplifying macrophage-mediated phagocytosis [55]. Another promising candidate, "AO-176", a next-generation anti-CD47 antibody, distinguishes itself with negligible red blood cell (RBC) binding. AO-176 induces tumor cytotoxicity through a unique mechanism, diverging from traditional CD47-targeting agents [56].

10.3. Regulatory Mechanisms

Cutting-edge research has identified microRNAs, such as "miR-101-5p", as key regulators of CD47 expression in diffuse large B-cell lymphoma. This discovery opens

the door to new therapeutic strategies where modulating such regulatory elements could enhance the efficacy of CD47-targeted treatments [49].

While these innovations are promising, the journey towards fully optimized CD47-targeted therapies is not without challenges. Recent clinical trial setbacks underscore the need for continued exploration and refinement of these approaches [50].

11. Expanding Therapeutic Potential Beyond Cancer

The synergy between CD47 blockade and tyrosine kinase inhibitors (TKIs) represents a promising frontier in oncology, particularly for enhancing tumor immunity and normalizing tumor vasculature. CD47, often termed the "don't eat me" signal, plays a pivotal role in immune evasion by inhibiting phagocytosis. By targeting CD47, not only is tumor immunity bolstered, but in cases such as non-small cell lung cancer (NSCLC), there is also potential for significant therapeutic enhancement [57] [58].

11.1. Mechanisms of Action

One of the key mechanisms involves "EGFR activation", which upregulates CD47 expression in tumors, thereby suppressing macrophage phagocytosis and promoting immune evasion [59]. Combining CD47 blockade with TKIs has been shown to enhance the efficacy of existing therapies, primarily by increasing macrophage activity and improving overall immune function [19].

11.2. Clinical Implications

The therapeutic potential of CD47-targeted therapies is increasingly being validated through clinical trials, which indicate promising improvements in patient outcomes [19] [58]. However, challenges remain, notably the issue of anemia caused by CD47 expression on erythrocytes, which must be meticulously managed [19].

Despite the focus on cancer, the role of CD47 in immune modulation suggests broader applications, even in non-neoplastic diseases. This highlights the necessity for ongoing research into CD47's mechanisms and the exploration of potential combinations with other treatments [60].

11.3. Personalized Approaches in Cancer Immunotherapies

The future of cancer immunotherapy lies in the complex harmony between targeted therapies and immune modulation, with a particular emphasis on CD47-SIRPα blockade and TKIs. This combined approach aims to not only enhance the immune response against tumors but also to overcome innate resistance mechanisms that often undermine treatment effectiveness.

11.4. Mechanisms of CD47-SIRPα Blockade

The interaction between CD47 and SIRPα, which signals macrophages to avoid consuming tumor cells, is a crucial target in cancer therapy. Blocking this interaction

has been shown to enhance antibody-dependent cellular phagocytosis (ADCP), especially in head and neck squamous cell carcinoma (HNSCC), where it synergizes effectively with "Cetuximab", a targeted therapy for HNSCC [44]. Furthermore, ATP release, driven by type I interferons, plays a pivotal role in T cell activation and the reprogramming of tumor metabolism, essential for the efficacy of CD47-SIRPα blockade [61].

11.5. Synergistic Effects with TKIs

Combining CD47-SIRPα blockade with TKIs has shown promise in preclinical models by enhancing macrophage function and restoring immune competency. This dual approach could potentially overcome the immune suppression prevalent in tumor microenvironments, offering a multifaceted attack on cancer [62].

In summary, while CD47-SIRPα blockade holds substantial promise for enhancing cancer immunotherapy, the risks, such as anemia and the critical importance of patient selection, must be carefully navigated for successful clinical implementation [19].

12. Conclusion

The review highlights the potential of combining CD47-SIRPα blockade with tyrosine kinase inhibitors (TKIs) as a promising cancer therapy strategy. While TKIs effectively target oncogenic pathways, they face challenges such as drug resistance and minimal residual disease. The addition of CD47-SIRPα blockade enhances antitumor immunity by disrupting immune evasion mechanisms, potentially leading to improved therapeutic outcomes. However, challenges like hematotoxicity, tumor heterogeneity, and an immunosuppressive tumor microenvironment must be addressed. Future research should focus on optimizing dosing, identifying suitable patient groups, and developing advanced delivery systems to overcome these hurdles. This combination approach could advance the development of durable and potentially curative cancer treatment strategies, offering significant progress in the field of oncology.

Authors' Contribution

All authors contributed to the study's conception, writing—review & editing. Mahamud Hirsi conceived and supervised the entire process. All authors read and approved of the final manuscript.

Data Availability

The data used to support the findings of this study are included in the article.

Conflicts of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

[1] Ciriello, G., Magnani, L., Aitken, S.J., Akkari, L., Behjati, S., Hanahan, D., *et al*. (2023) Cancer Evolution: A Multifaceted Affair. *Cancer Discovery*, **14**, 36-48. https://doi.org/10.1158/2159-8290.cd-23-0530

[2] Barclay, A.N. and van den Berg, T.K. (2014) The Interaction between Signal Regulatory Protein Alpha (SIRP*α*) and CD47: Structure, Function, and Therapeutic Target. *Annual Review of Immunology*, **32**, 25-50. https://doi.org/10.1146/annurev-immunol-032713-120142

[3] Josef, K., Jan, N., Jaroslav, M. and Oleksandr, N. (2013) Mathematical Model for Cancer Prevalence and Cancer Mortality. https://tvim.su/files/044-054%20Kalas%20Novotny%20Michalek%20Nakonechny.pdf

[4] Lunt, N. (2023) The Global Challenge of Cancer Governance. *World Medical & Health Policy*, **15**, 672-681. https://doi.org/10.1002/wmh3.577

[5] Cabanos, H.F. and Hata, A.N. (2021) Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer. *Cancers*, **13**, Article 2666. https://doi.org/10.3390/cancers13112666

[6] Mancini, C., Lori, G., Pranzini, E. and Taddei, M.L. (2024) Metabolic Challengers Selecting Tumor-Persistent Cells. *Trends in Endocrinology & Metabolism*, **35**, 263-276. https://doi.org/10.1016/j.tem.2023.11.005

[7] Chuang, C., Zhen, Y., Ma, J., Lee, T., Hung, H., Wu, C., *et al*. (2024) CD47-Mediated Immune Evasion in Early-Stage Lung Cancer Progression. *Biochemical and Biophysical Research Communications*, **720**, Article ID: 150066. https://doi.org/10.1016/j.bbrc.2024.150066

[8] Polara, R., Ganesan, R., Pitson, S.M. and Robinson, N. (2024) Cell Autonomous Functions of CD47 in Regulating Cellular Plasticity and Metabolic Plasticity. *Cell Death & Differentiation*, **31**, 1255-1266. https://doi.org/10.1038/s41418-024-01347-w

[9] Abd alkareem, F.O. and Mohamad, B.J. (2024) Immunohistochemical Expression and Histopathological Role of CD47 in Colorectal Cancer in Iraqi Patients. *Journal of the Faculty of Medicine Baghdad*, **66**, 122-128. https://doi.org/10.32007/jfacmedbagdad.6622275

[10] Xing, L., Wang, Z., Feng, Y., Luo, H., Dai, G., Sang, L., *et al*. (2024) The Biological Roles of CD47 in Ovarian Cancer Progression. *Cancer Immunology, Immunotherapy*, **73**, Article No. 145. https://doi.org/10.1007/s00262-024-03708-3

[11] Wu, F., Pang, H., Li, F., Hua, M., Song, C. and Tang, J. (2024) Progress in Cancer Research on the Regulator of Phagocytosis CD47, Which Determines the Fate of Tumor Cells (Review). *Oncology Letters*, **27**, Article No. 256. https://doi.org/10.3892/ol.2024.14389

[12] Yang, Y., Wu, H., Yang, Y., Kang, Y., He, R., Zhou, B., *et al*. (2023) Dual Blockade of CD47 and CD24 Signaling Using a Novel Bispecific Antibody Fusion Protein Enhances Macrophage Immunotherapy. *Molecular Therapy—Oncolytics*, **31**, Article ID: 100747. https://doi.org/10.1016/j.omto.2023.100747

[13] Sue, M., Tsubaki, T., Ishimoto, Y., Hayashi, S., Ishida, S., Otsuka, T., *et al*. (2024) Blockade of SIRP*α*-Cd47 Axis by Anti-SIRP*α* Antibody Enhances Anti-Tumor Activity of DXd Antibody-Drug Conjugates. *PLOS ONE*, **19**, e0304985. https://doi.org/10.1371/journal.pone.0304985

[14] Hussain, S., Mursal, M., Verma, G., Hasan, S.M. and Khan, M.F. (2024) Targeting Oncogenic Kinases: Insights on FDA Approved Tyrosine Kinase Inhibitors. *European*

Journal of Pharmacology, **970**, Article ID: 176484.
https://doi.org/10.1016/j.ejphar.2024.176484

[15] Li, J., Gong, C., Zhou, H., Liu, J., Xia, X., Ha, W., *et al*. (2024) Kinase Inhibitors and Kinase-Targeted Cancer Therapies: Recent Advances and Future Perspectives. *International Journal of Molecular Sciences*, **25**, Article No. 5489.
https://doi.org/10.3390/ijms25105489

[16] Jie, X.-L., Kong, Y.-Y. and Zhou, G.-B. (2023) Latest Findings on the Role of CD47 in Tumor Immune Evasion and Related Targeted Therapies. *Journal of Sichuan University. Medical Science Edition*, **54**, 455-461.

[17] Hu, L., Zhuang, W., Chen, M., Liao, J., Wu, D., Zhang, Y., *et al*. (2024) EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion through Up-Regulation of CD47. *Journal of Thoracic Oncology*, **19**, 1186-1200.
https://doi.org/10.1016/j.jtho.2024.03.019

[18] Liang, H., Zheng, Y., Huang, Z., Dai, J., Yao, L., Xie, D., *et al*. (2024) Pan-Cancer Analysis for the Prognostic and Immunological Role of CD47: Interact with TNFRSF9 Inducing CD8+ T Cell Exhaustion. *Discover Oncology*, **15**, Article No. 149.
https://doi.org/10.1007/s12672-024-00951-z

[19] Liu, Y., Weng, L., Wang, Y., Zhang, J., Wu, Q., Zhao, P., *et al*. (2024) Deciphering the Role of CD47 in Cancer Immunotherapy. *Journal of Advanced Research*, **63**, 129-158.
https://doi.org/10.1016/j.jare.2023.10.009

[20] Huang, K., Liu, Y., Wen, S., Zhao, Y., Ding, H., Liu, H., *et al*. (2023) Binding Mechanism of CD47 with SIRPα Variants and Its Antibody: Elucidated by Molecular Dynamics Simulations. *Molecules*, **28**, Article No. 4610.
https://doi.org/10.3390/molecules28124610

[21] Morrissey, M.A., Kern, N. and Vale, R.D. (2020) CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis. *Immunity*, **53**, 290-302.e6. https://doi.org/10.1016/j.immuni.2020.07.008

[22] Wang, J., Tseng, C., Teng, H., Kuo, P., Cheng, Y., Chen, Y., *et al*. (2022) 496 HCB101: A Safe and Effective Ligand Trap Therapeutic Targeting the CD47-SIRPα Signaling Pathway for Cancer Treatment. *Journal for ImmunoTherapy of Cancer*, **10**, A517.

[23] Wang, B., Pan, L., Chen, M., Ma, Y., Gao, J., Tang, D., *et al*. (2023) SIRP-Alpha-IL-6 Axis Induces Immunosuppressive Macrophages in Non-Small-Cell Lung Cancer. *Biochemical and Biophysical Research Communications*, **682**, 386-396.
https://doi.org/10.1016/j.bbrc.2023.10.035

[24] Chen, W., Li, X., Wang, J., Song, N., Zhu, A. and Jia, L. (2019) miR-378a Modulates Macrophage Phagocytosis and Differentiation through Targeting CD47-SIRPα Axis in Atherosclerosis. *Scandinavian Journal of Immunology*, **90**, e12766.
https://doi.org/10.1111/sji.12766

[25] Gajendran, N., Hernandez, M.G., Yende, A., Alahmadi, Z., Li, X., Munoz, Z., *et al*. (2023) Abstract 666: Targeting the CD47/SIRPα "Do Not Eat Me" Phagocytic Pathway in Macrophages to Improve Anti-CD47 Immune Therapy. *Cancer Research*, **83**, 666-666. https://doi.org/10.1158/1538-7445.am2023-666

[26] Wang, Q.Q., *et al*. (2023) Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer. *Journal of Immunology Research*, **2023**, Article ID: 2473075.

[27] Zimarino, C., Moody, W., Davidson, S.E., Munir, H. and Shields, J.D. (2024) Disruption of CD47-SIRPα Signaling Restores Inflammatory Function in Tumor-Associated Myeloid-Derived Suppressor Cells. *iScience*, **27**, Article ID: 109546.
https://doi.org/10.1016/j.isci.2024.109546

[28] Biedermann, A., Patra-Kneuer, M., Mougiakakos, D., Büttner-Herold, M., Mangelberger-Eberl, D., Berges, J., *et al*. (2024) Blockade of the CD47/SIRP*α* Checkpoint Axis Potentiates the Macrophage-Mediated Anti-Tumor Efficacy of Tafasitamab. *Haematologica*, **109**, 3928-3940. https://doi.org/10.3324/haematol.2023.284795

[29] Lim, H.Y., Ahn, J.S., Park, J.O., Yong Hong, J., Seon, H., Lee, J.K., *et al*. (2023) 1035P Phase I Dose Escalation Study of IMC-002, a Novel Anti-Cd47 Monoclonal Antibody, in Patients with Advanced Solid Tumors. *Annals of Oncology*, **34**, S629. https://doi.org/10.1016/j.annonc.2023.09.2174

[30] Zhang, Q., Liu, A., Shi, J., Cai, Q., Qu, Z., Liu, S., *et al*. (2023) A First-in-Human Study of MIL95, an Anti-CD47 Monoclonal Antibody (mAb), in Patients with Advanced Solid Tumors and Lymphomas. *Journal of Clinical Oncology*, **41**, e14513. https://doi.org/10.1200/jco.2023.41.16_suppl.e14513

[31] Osorio, J.C., Smith, P., Knorr, D.A. and Ravetch, J.V. (2023) The Antitumor Activities of Anti-CD47 Antibodies Require Fc-Fc*γ*R Interactions. *Cancer Cell*, **41**, 2051-2065.e6. https://doi.org/10.1016/j.ccell.2023.10.007

[32] Li, Y., Liu, J., Chen, W., Wang, W., Yang, F., Liu, X., *et al*. (2023) A pH-Dependent Anti-CD47 Antibody That Selectively Targets Solid Tumors and Improves Therapeutic Efficacy and Safety. *Journal of Hematology & Oncology*, **16**, Article No. 2. https://doi.org/10.1186/s13045-023-01399-4

[33] Tian, W., Li, S., Chen, D., Yang, Y., Guo, H., Liu, D., *et al*. (2024) Abstract LB129: Preclinical Development of a Bispecific Antibody-Trap Selectively Targeting CD38 and CD47 for Treating Hematologic Malignancies. *Cancer Research*, **84**, LB129. https://doi.org/10.1158/1538-7445.am2024-lb129

[34] Baek, B.S., Kim, M.G., Kim, J.H., Jang, I.Y., Kim, S.M., Kim, J.H., *et al*. (2024) Abstract 2719: Papiliximab, a Bispecific Nanobody Targeting CD47 and PDL1 Retards Tumor Growth without Hemolysis. *Cancer Research*, **84**, 2719-2719. https://doi.org/10.1158/1538-7445.am2024-2719

[35] Zhang, K., Xu, Y., Chang, X., Xu, C., Xue, W., Ding, D., *et al*. (2024) Co-Targeting CD47 and VEGF Elicited Potent Anti-Tumor Effects in Gastric Cancer. *Cancer Immunology, Immunotherapy*, **73**, Article No. 75. https://doi.org/10.1007/s00262-024-03667-9

[36] Combarel, D., Dousset, L., Bouchet, S., Ferrer, F., Tetu, P., Lebbe, C., *et al*. (2024) Tyrosine Kinase Inhibitors in Cancers: Treatment Optimization—Part I. *Critical Reviews in Oncology/Hematology*, **199**, Article ID: 104384. https://doi.org/10.1016/j.critrevonc.2024.104384

[37] Ferrer, F., Tetu, P., Dousset, L., Lebbe, C., Ciccolini, J., Combarel, D., *et al*. (2024) Tyrosine Kinase Inhibitors in Cancers: Treatment Optimization—Part II. *Critical Reviews in Oncology/Hematology*, **200**, Article ID: 104385. https://doi.org/10.1016/j.critrevonc.2024.104385

[38] Costa, A., Abruzzese, E., Latagliata, R., Mulas, O., Carmosino, I., Scalzulli, E., *et al*. (2024) Safety and Efficacy of TKIs in Very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia. *Journal of Clinical Medicine*, **13**, Article No. 273. https://doi.org/10.3390/jcm13010273

[39] Zhang, X.S, Liu, B.C., Huang, J., *et al*. (2024) A Predictive Model for Therapy Failure in Chronic Myeloid Leukemia Patients Receiving Tyro-Sine Kinase Inhibitor Therapy. *Blood*, **144**, 1951-1961.

[40] Jeong, S.U., Park, J., Yoon, S.Y., Hwang, H.S., Go, H., Shin, D., *et al*. (2024) Ifitm3-Mediated Activation of TRAF6/MAPK/AP-1 Pathways Induces Acquired TKI Resistance in Clear Cell Renal Cell Carcinoma. *Investigative and Clinical Urology*, **65**, 84-93. https://doi.org/10.4111/icu.20230294

[41] Wang, Q., Yang, S., Wang, K. and Sun, S. (2019) MET Inhibitors for Targeted Therapy of EGFR TKI-Resistant Lung Cancer. *Journal of Hematology & Oncology*, **12**, Article No. 63. https://doi.org/10.1186/s13045-019-0759-9

[42] Stone, L. (2017) Targeted Therapies: Reversal of Fortunes for TKI Resistance. *Nature Reviews Clinical Oncology*, **14**, 263-263. https://doi.org/10.1038/nrclinonc.2017.33

[43] Park, H., Kim, S., Keam, B., Chung, H., Seok, S.H., Kim, S., *et al*. (2022) Blockade of CD47 Enhances the Antitumor Effect of Macrophages in Renal Cell Carcinoma through Trogocytosis. *Scientific Reports*, **12**, Article No. 12546. https://doi.org/10.1038/s41598-022-16766-3

[44] Li, B., Hao, Y., He, H., Fan, Y., Ren, B., Peng, X., *et al*. (2024) CD47-SIRP*α* Blockade Sensitizes Head and Neck Squamous Cell Carcinoma to Cetuximab by Enhancing Macrophage Adhesion to Cancer Cells. *Cancer Research*, **84**, 3189-3206. https://doi.org/10.1158/0008-5472.can-24-0176

[45] Nishiga, Y., Drainas, A.P., Baron, M., Bhattacharya, D., Barkal, A.A., Ahrari, Y., *et al*. (2022) Radiotherapy in Combination with CD47 Blockade Elicits a Macrophage-Mediated Abscopal Effect. *Nature Cancer*, **3**, 1351-1366. https://doi.org/10.1038/s43018-022-00456-0

[46] Tang, L., Yin, Y., Cao, Y., Fu, C., Liu, H., Feng, J., *et al*. (2023) Extracellular Vesicles-derived Hybrid Nanoplatforms for Amplified CD47 Blockade-Based Cancer Immunotherapy. *Advanced Materials*, **35**, e2303835. https://doi.org/10.1002/adma.202303835

[47] Shen, Y., Ji, M., Yi, H., Shen, R., Fu, D., Cheng, S., *et al*. (2024) CD47 Overexpression Is Related to Tumour-Associated Macrophage Infiltration and Diffuse Large B-Cell Lymphoma Progression. *Clinical and Translational Medicine*, **14**, e1532. https://doi.org/10.1002/ctm2.1532

[48] Boardman, A.P., James, S. and Van Den Brink, M.R.M. (2023) Targeting CD47 in Lymphoid Malignancies with CAR T Cells. *Journal of Clinical Oncology*, **41**, 2513-2513. https://doi.org/10.1200/jco.2023.41.16_suppl.2513

[49] Masroni, M.S.b., Leong, S.M., Cheng, H., Lim, G.S., Heng, N.Z.Y., Law, C.T., *et al*. (2023) miR-101-5p Modulation of CD47 in Diffuse Large B-Cell Lymphoma: Implications for Anti-CD47 Immunotherapy and Prognostication. *British Journal of Haematology*, **204**, 730-734. https://doi.org/10.1111/bjh.19264

[50] Jiang, C., Sun, H., Jiang, Z., Tian, W., Cang, S. and Yu, J. (2024) Targeting the CD47/SIRP*α* Pathway in Malignancies: Recent Progress, Difficulties and Future Perspectives. *Frontiers in Oncology*, **14**, Article ID: 1378647. https://doi.org/10.3389/fonc.2024.1378647

[51] Chen, Y., Shi, W., Shi, J. and Lu, J. (2021) Progress of CD47 Immune Checkpoint Blockade Agents in Anticancer Therapy: A Hematotoxic Perspective. *Journal of Cancer Research and Clinical Oncology*, **148**, 1-14. https://doi.org/10.1007/s00432-021-03815-z

[52] Fu, Z., Feng, M., Wu, J., Liu, B., Fu, J. and Song, W. (2024) Photodynamic Therapy Synergizes CD47 Blockade Strategy for Enhanced Antitumor Therapy. *Molecular Pharmaceutics*, **21**, 3897-3908. https://doi.org/10.1021/acs.molpharmaceut.4c00254

[53] Hilinski, G., Stearns, B., Vibhute, S., Hughes, T., Tridandapani, S., Johnstone, M.E., *et al*. (2023) The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy. *Blood*, **142**, 4692-4692. https://doi.org/10.1182/blood-2023-189238

[54] Creeden, J.F., Sevier, J., Zhang, J., Lapitsky, Y., Brunicardi, F.C., Jin, G., *et al*. (2024) Smart Exosomes Enhance PDAC Targeted Therapy. *Journal of Controlled Release*, **368**,

413-429. https://doi.org/10.1016/j.jconrel.2024.02.037

[55] Wang, T., Wang, S., Du, Y., Sun, D., Liu, C., Liu, S., *et al*. (2024) Gentulizumab, a Novel Anti-Cd47 Antibody with Potent Antitumor Activity and Demonstrates a Favorable Safety Profile. *Journal of Translational Medicine*, **22**, Article No. 220. https://doi.org/10.1186/s12967-023-04710-6

[56] Puro, R.J., Bouchlaka, M.N., Hiebsch, R.R., Capoccia, B.J., Donio, M.J., Manning, P.T., *et al*. (2020) Development of AO-176, a Next-Generation Humanized Anti-Cd47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding. *Molecular Cancer Therapeutics*, **19**, 835-846. https://doi.org/10.1158/1535-7163.mct-19-1079

[57] Zhuang, Z., Zhou, J., Qiu, M., Li, J., Lin, Z., Yi, H., *et al*. (2024) The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment. *Cancers*, **16**, Article No. 832. https://doi.org/10.3390/cancers16040832

[58] Lau, A.P.Y., Khavkine Binstock, S.S. and Thu, K.L. (2023) CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer. *Cancers*, **15**, Article No. 5229. https://doi.org/10.3390/cancers15215229

[59] Du, L., Su, Z., Wang, S., Meng, Y., Xiao, F., Xu, D., *et al*. (2023) EGFR-Induced and C-SRC-Mediated CD47 Phosphorylation Inhibits Trim21-Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion. *Advanced Science*, **10**, Article ID: 2206380. https://doi.org/10.1002/advs.202206380

[60] Wang, C., Feng, Y., Patel, D., Xie, H., Lv, Y. and Zhao, H. (2023) The Role of CD47 in Non-Neoplastic Diseases. *Heliyon*, **9**, e22905. https://doi.org/10.1016/j.heliyon.2023.e22905

[61] Zhou, H., Wang, W., Xu, H., Liang, Y., Ding, J., Lv, M., *et al*. (2024) Metabolic Reprograming Mediated by Tumor Cell-Intrinsic Type I IFN Signaling Is Required for CD47-SIRPα Blockade Efficacy. *Nature Communications*, **15**, Article No. 5759. https://doi.org/10.1038/s41467-024-50136-z

[62] Jin, S., Wang, H., Li, Y., Yang, J., Li, B., Shi, P., *et al*. (2024) Discovery of a Novel Small Molecule as CD47/SIRPα and PD-1/PD-L1 Dual Inhibitor for Cancer Immunotherapy. *Cell Communication and Signaling*, **22**, Article No. 173. https://doi.org/10.1186/s12964-024-01555-4